INVOKANA®

Drug Information Related Patent

Hold Company

JANSSEN PHARMS

Learn More

Dosage and Administration

TABLET;ORAL

Specification

100MG; 300MG

Indication

INVOKANA® improves glycemic control and reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) as an adjunct to diet and exercise. It can also be used to reduce the end-stage renal disease, doubling of serum creatinine, cardiovascular (CV) and death associated with proteinuria > 300 mg/day in patients with type 2 diabetes mellitus and diabetic nephropathy risk of hospitalization for heart failure.

Use

Instructions for Use

API

CANAGLIFLOZIN

API Structure

We Supply

CANAGLIFLOZIN

Note:

In-house Standard
Facility GMP
CDE/USMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
10617668	2031/5/11
7943582	2029/2/26
7943788	2027/7/14
8222219	2025/4/11
8513202	2027/12/3

API Patent

Patent No	Expiration Date
7943582	2029/2/26
7943788	2027/7/14
8222219	2025/4/11
8513202	2027/12/3

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION